A New Scoring System for the Assessment of Neonatal Abstinence Syndrome

Abstract

Objective This study aimed to evaluate the concordance of a new scoring system for neonatal abstinence syndrome (NAS) and NAS scores to the traditional Modified Finnegan Neonatal Abstinence Scoring Tool (M-FNAST) score. The NAS score is based on the physiology of withdrawal, with equal emphasis on behavior, and neurological signs.

Study Design The NAS scores for a control group of 202 healthy, term neonates were compared with those for 45 term neonates with NAS. The NAS and M-FNAST scores obtained simultaneously in 45 term neonates with NAS were compared using correlation, linear regression, and receiver operating characteristic curve analysis to determine the validity, reliability, and specificity of the NAS scores.

Results The association between the NAS and M-FNAST scores was high (Spearman's correlation, 83%; linear regression, 83%), with an area under the curve of the NAS score of 1.00 (p < 0.01). A cut-off NAS score ≥4 identified NAS neonates with a sensitivity of 100% and specificity of 96%. The values of intraclass correlation, interrater agreement, and Cronbach's α were 0.63, 0.88, and 0.63, respectively.

Conclusion The new NAS scoring system is valid, reliable, physiologically based, and correlates closely with the M-FNAST score. The NAS scores may require further validation before its use in clinical practice.

Keywords

neonatal abstinence syndrome - NAS scores - withdrawal - physiological

• References

• 1 Kocherlakota P. Neonatal abstinence syndrome. Pediatrics 2014; 134 (02) e547-e561
• 2 Hudak ML, Tan RC. ; Committee on Drugs; Committee on Fetus and Newborn; American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics 2012; 129 (02) e540-e560
• 3 McQueen K, Murphy-Oikonen J. Neonatal abstinence syndrome. N Engl J Med 2016; 375 (25) 2468-2479
• 4 Kaltenbach K. Assessment of the newborn prenatally exposed to drugs: The history. Semin Fetal Neonatal Med 2019; 24 (02) 111-114
• 5 Finnegan LP, Connaughton Jr JF, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. Addict Dis 1975; 2 (1,2): 141-158
• 6 Lipsitz PJ. A proposed narcotic withdrawal score for use with newborn infants. A pragmatic evaluation of its efficacy. Clin Pediatr (Phila) 1975; 14 (06) 592-594
• 7 Ostrea EM, Chavez CJ, Strauss ME. A study of factors that influence the severity of neonatal narcotic withdrawal. J Pediatr 1976; 88 (4, Pt. 1): 642-645
• 8 Green M, Suffet F. The Neonatal Narcotic Withdrawal Index: a device for the improvement of care in the abstinence syndrome. Am J Drug Alcohol Abuse 1981; 8 (02) 203-213
• 9 Mehta A, Forbes KD, Kuppala VS. Neonatal abstinence syndrome management from prenatal counselling to post discharge follow-up care: Results of a national survey. Hosp Pediatr 2013; 3 (04) 317-323
• 10 Finnegan L, Kaltenbach K. Neonatal abstinence syndrome. In Hoekelman R, Friedman S, Nelson N, Seidel H. eds. Pediatric Primary Care. 2nd ed. St. Louis, MO: Mosby; 1992
• 11 Wolff K, Perez-Montejano R. Opioid neonatal abstinence syndrome: controversies and implications for practice. Curr Drug Abuse Rev 2014; 7 (01) 44-58
• 12 Schiff DM, Grossman MR. Beyond the Finnegan scoring system: novel assessment and diagnostic techniques for the opioid-exposed infant. Semin Fetal Neonatal Med 2019; 24 (02) 115-120
• 13 D'Apolito KC. Assessing neonates for neonatal abstinence: are you reliable?. J Perinat Neonatal Nurs 2014; 28 (03) 220-231
• 14 Wachman EM, Grossman M, Schiff DM. , et al. Quality improvement initiative to improve inpatient outcomes for neonatal abstinence syndrome. J Perinatol 2018; 38 (08) 1114-1122
• 15 Kraft WK, Adeniyi-Jones SC, Chervoneva I. , et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. N Engl J Med 2017; 376 (24) 2341-2348
• 16 Jones HE, Seashore C, Johnson E. , et al. Psychometric assessment of the neonatal abstinence scoring system and the MOTHER NAS scale. Am J Addict 2016; 25 (05) 370-373
• 17 Bagley SM, Wachman EM, Holland E, Brogly SB. Review of the assessment and management of neonatal abstinence syndrome. Addict Sci Clin Pract 2014; 9 (01) 19
• 18 Patrick SW, Schumacher RE, Horbar JD. , et al. Improving care for neonatal abstinence syndrome. Pediatrics 2016; 137 (05) e20153835
• 19 Timpson W, Killoran C, Maranda L, Picarillo A, Bloch-Salisbury E. A Quality improvement initiative to increase scoring consistency and accuracy of the Finnegan tool: Challenges in obtaining reliable assessments of drug withdrawal in neonatal abstinence syndrome. Adv Neonatal Care 2018; 18 (01) 70-78
• 20 Jones HE, Seashore C, Johnson E, Horton E, O'Grady KE, Andringa K. Measurement of neonatal abstinence syndrome: evaluation of short forms. J Opioid Manag 2016; 12 (01) 19-23
• 21 Maguire D, Cline GJ, Parnell L, Tai CY. Validation of the Finnegan neonatal abstinence syndrome tool-short form. Adv Neonatal Care 2013; 13 (06) 430-437
• 22 Gomez Pomar E, Finnegan LP, Devlin L. , et al. Simplification of the Finnegan Neonatal Abstinence Scoring System: retrospective study of two institutions in the USA. BMJ Open 2017; 7 (09) e016176
• 23 Grossman MR, Berkwitt AK, Osborn RR. , et al. An initiative to improve the quality of care of infants with neonatal abstinence syndrome. Pediatrics 2017; 139 (06) e20263360
• 24 Kocherlakota P, Qian E, Patel V, Mandru C, Vilar R. NA-S-CORE, A New Scoring System for the Management of NAS presented at Eastern Society of Pediatric Research Annual Meeting. Philadelphia. PA, March 24–26, 2017
• 25 Qian E, Patel V, Mandru C, Vilar R, Kocherlakota P. NA-S-CORE New Scoring System for the Management of Neonatal Abstinence Syndrome presented at American Academy of Pediatrics Experience National Conference and Exhibition, Chicago, IL, September 16–19, 2017
• 26 Streiner DL. Starting at the beginning: an introduction to coefficient alpha and internal consistency. J Pers Assess 2003; 80 (01) 99-103
• 27 Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33 (01) 159-174
• 28 Jansson LM, Velez M, Harrow C. The opioid-exposed newborn: assessment and pharmacologic management. J Opioid Manag 2009; 5 (01) 47-55
• 29 Finnegan LP, Kron RE, Connaughton JF, Emich JP. Assessment and treatment of abstinence in the infant of the drug-dependent mother. Int J Clin Pharmacol Biopharm 1975; 12 (1,2): 19-32
• 30 Little PJ, Price RR, Hinton RK, Kuhn CM. Role of noradrenergic hyperactivity in neonatal opiate abstinence. Drug Alcohol Depend 1996; 41 (01) 47-54
• 31 Elliott MR, Cunliffe P, Demianczuk N, Robertson CMT. Frequency of newborn behaviours associated with neonatal abstinence syndrome: a hospital-based study. J Obstet Gynaecol Can 2004; 26 (01) 25-34
• 32 Cheshire Jr WP, Goldstein DS. The physical examination as a window into autonomic disorders. Clin Auton Res 2018; 28 (01) 23-33
• 33 van Stralen KJ, Jager KJ, Zoccali C, Dekker FW. Agreement between methods. Kidney Int 2008; 74 (09) 1116-1120
• 34 Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1 (8476): 307-310